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Decreased expression of stomatin predicts
poor prognosis in HER2-positive breast
cancer
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Abstract
Background: Human epidermal growth factor receptor-2 (HER2) is a transmembrane tyrosine kinase receptor that
is overexpressed in 25 to 30 % of human breast cancers and is preferentially localized in lipid rafts. Stomatin is a
membrane protein that is absent from the erythrocyte plasma membrane in patients with congenital
stomatocytosis and is the major component of the lipid raft.
Results: In a total of 68 clinical cases of HER2-positive breast cancer, the absence of stomatin expression was
associated with a decreased 5-year survival (65 % vs. 93 %, p = 0.005) by survival analysis. For stage I-III HER2-positive
breast cancer, the absence of stomatin expression was associated with a decreased 5-year disease-free survival
(57 % vs. 81 %, p = 0.016) and was an independent prognostic factor by multivariate analysis. Negative stomatin
expression predicts distant metastases in a hazard ratio of 4.0 (95 % confidence interval from 1.3 to 12.5).
Conclusions: These results may suggest that stomatin is a new prognostic indicator for HER2-positive breast
cancer.
Keywords: Breast cancer, Stomatin, HER2, Tumor biomarkers
Abbreviations: AUC, Area under curve; CI, Confidence interval; CMF, Classical CMF chemotherapy, including
cyclophosphamide, methotrexate, and fluorouracil; ER, Estrogen receptor; FISH, Fluorescence in situ hybridization;
HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; ROC, Receiver operating curve
Background
Human epidermal growth factor receptor-2 (HER2) is an
important transmembrane tyrosine kinase receptor that
is overexpressed in 25 to 30 % of human breast cancers
[1]. The HER2 receptor is able to promote cell prolifera-
tion and is preferentially localized in lipid rafts, which
are special sphingolipid-rich and cholesterol-rich mem-
brane microdomains; these microdomains control acti-
vation HER2 by decreasing HER2 homodimerization
and lowering the subsequent spontaneous activation of
the receptor [2]. Trastuzumab (Herceptin®) is a human-
ized monoclonal antibody that binds to HER2 and
inhibits the proliferation and survival of HER2-positive
breast cancers [3].
Stomatin is a membrane protein that is absent from
the erythrocyte plasma membrane in patients with con-
genital haemolytic anaemia or stomatocytosis [4, 5].
Northern blot analysis has revealed a widespread cellular
distribution of stomatin in reticulocytes, bone marrow,
kidney, brain, gut and heart as well as various cell lines
[6]. Stomatin is the major component of the lipid raft in
the plasma membrane of epithelial cell lines, erythro-
cytes, and platelet alpha granules [7–11]. Two of the few
well-known functions of stomatin are, firstly, the direct
modulation of the activity of the acid-sensing ion chan-
nel and, secondly, the control of glucose transporter type
1 activity [12, 13]. In addition, it has been shown that
hypoxia up-regulates stomatin expression in the cerebral
cortex of rats and alveolar epithelial cells [14, 15]. How-
ever, since the discovery of the stomatin in 1982, the
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function of stomatin across a range of different tissues
still remains unknown [4, 6, 16].
Stomatin has been shown to have decreased expres-
sion in cancer cells [17]. According to the Swedish Hu-
man Protein Atlas project, immunohistochemical
analysis of stomatin protein expression reveals that more
than 75 % of normal breast glandular and myoepithelial
cells are strongly positive for this protein [18]. In con-
trast, in breast cancer, the expression of stomatin in
these cells was 31 % (7/23) negative, 39 % weak (9/23),
26 % moderate (6/23), and 4 % (1/23) strong positive
when tissue microarrays were analyzed by immunohisto-
chemistry [18].
Although stomatin is expressed in a significant propor-
tion of breast cancers, the relationship between stomatin
expression and breast cancer has not been explored in
detail. Recently reported by Arkhipova and colleagues in
2014, stomatin is down-regulated in non-small cell lung
cancer and is associated with lymph node metastases
[19]. This is the first and the only one study to demon-
strate that stomatin has a role in carcinogenesis. In com-
parison, stomatin-like protein 2, which shows a high
degree of sequence similarity to stomatin, had been re-
ported to be associated with a decreased overall survival
among breast cancer [20], pulmonary squamous carcin-
oma [21], glioma [22], endometrial adenocarcinoma
[23], laryngeal squamous carcinoma [24], esophageal
squamous carcinoma [25] and colorectal cancer [26]
patients.
Stomatin is the major component of lipid raft where
HER2 is known to be clustered and therefore it seems
likely that stomatin expression may have an impact on
the pathology of HER2-positive breast cancer. In the
present study, the relationship of stomatin expression
and the clinical survival outcome was explored for pa-
tients with HER2-positive breast cancer.
Methods
The archival formalin-fixed paraffin-embedded tissue
samples obtained from women diagnosed of infiltrating
ductal carcinoma of female breast from 2001 to 2012. The
women of histologies other than infiltrating ductal carcin-
oma were excluded. All HER2-positive cases were either
HER2 immunohistochemistry 3+ or 2+ (medium positive)
which was further confirmed by fluorescence in situ
hybridization (FISH) to identify HER2 gene amplification
[27]. There were 5 cases excluded where the HER2 immu-
nohistochemistry results were 2 + but the FISH studies
failed. Tumor grade was defined according to the (Scarff)
Bloom-Richardson (BR) grading system. The results for
ER, PR, and HER2 were obtained from the medical re-
cords. Cases where ER and PR were found in more than
5 % of the tumor cells were considered to be positive.
Cancer staging was based on the American Joint
Committee on Cancer (AJCC seventh Edition). All the pa-
tients were operated by either one of the two breast sur-
geons (C-Y Chen and S-S Lo). Chemotherapy was given
according to the institutional guidelines and policy of Na-
tional Health Insurance Administration in Taiwan.
Anthracycline chemotherapy was unrestricted but taxane
chemotherapy was insurance-paid only for patients whose
cancer was locally advanced or metastatic. For targeted
therapy, palliative trastuzumab therapy was insurance-
paid when distant metastasis occurred. In patients without
a distant event, adjuvant trastuzumab was insurance-paid
for patients with positive lymph node status and this pol-
icy was only effective after 2010. The duration of trastuzu-
mab therapy was allowed for 1 year at most. In this study,
no patient had ever received targeted therapy other than
trastuzumab. The study was held in the National Yang-
Ming University Hospital, located in the north I-Lan
County, Taiwan. The clinical outcomes of the patients
were surveyed until December 31, 2014. Institutional re-
view board approval was obtained before acquisition of
patient health information.
Tissue sections (4 μm thick) were subjected to heat-
induced antigen retrieval in the presence of 0.01 M so-
dium citrate buffer, pH 6.0 for 30 min using a pressure
boiler. Immunohistochemical staining was performed
using a polyclonal primary antibody against stomatin
(Atlas, HPA011419, Uppsala, Sweden) that was diluted
at 1:400; incubation took place for 30 min. Positive con-
trol was selected from breast cancer tissue of known
strong positive immunoreactivity for stomatin expres-
sion. Negative control experiments were conducted by
replacing the primary antibody with phosphate-buffered
saline.
Immunostaining was scored by the researcher (C-Y
Chen) and the junior pathologist (Y-C Chen), who were
blinded to the patients’ outcome and other clinicopatho-
logical parameters. Discordant scores were reevaluated
by the senior pathologist (C-W Shih), and a consensus
score was used for further analysis. Two features, inten-
sity and extent of immunoreactivity, were assessed as de-
scribed in a previous report by Chang and colleagues
[21]. The intensity of the immunostaining was classified
in four categories: 0, no brown particles in the tumor
cytoplasm or cell membrane; 1, faint brown staining of
cell membrane; 2, weak but definite brown staining of
cell membrane; and 3, deep brown staining of cell mem-
brane together with staining of cytoplasm (Fig. 1). The
percentage of positive cells were determined and classi-
fied into four groups: 1, fewer than 25 % positive tumor
cells; 2, 25 to 50 % positive tumor cells; 3, 51 to 75 %
positive tumor cells; and 4, more than 75 % positive
tumor cells. The immunostaining index was the product
of the two scores. We produced time-dependent receiver
operating characteristics (ROC) curves [28, 29] for
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evaluation of the immunostaining indices. Area under
curve (AUC) at 2- and 5-year survival was 0.765 and
0.543, respectively, suggesting a decrease in the statis-
tical power of stomatin immunoreactivity over time,
which may be explained by the early relapse of the
HER2-positive breast cancer. The optimal cutoff values
were 2 for 5-year-survival ROC and 7 for 2-year-survival
ROC. Therefore, we defined positive expression of sto-
matin protein as a staining index of 4 or more, while a
staining index from 0 to 3 was indicative of negative sto-
matin expression.
Statistical analyses were performed using STATA for
Windows 10.0 (StataCorp, College Station, TX). The
Student’s t test and Fisher’s exact test were used for stat-
istical analysis as appropriate. We estimated the survival
curves using the Kaplan-Meier product limit method
[30]. Breast cancer death was defined as death related to
distant metastases. Distant disease-free survival was de-
fined as time to distant metastasis, excluding local or re-
gional recurrence. The log-rank test was used to assess
the association of survival with stomatin expression. Cox
regression analysis was performed to compute hazard ra-
tios and 95 % confidence intervals (CI) and to evaluate
the effects of confounding factors during the multivari-
ate analysis. For all statistical tests, p < 0.05 was consid-
ered to be significant. All p values were two-sided.
Results
Using 68 HER2-positive and 58 HER2-negative samples
of infiltrating ductal carcinomas of the female breast,
stomatin protein expression was found to be localized
mainly in the plasma membrane and partially in the
cytosol. For HER2-positive patients, the overall immuno-
histochemistry staining results showed weak or absent
staining (staining index <4) in 32 cases (47 %) and posi-
tive staining (staining index ≥4) in 36 cases (53 %).
There was no statistical difference in patient age, cancer
grade, cancer stage, and expression of estrogen receptor/
progesterone receptor among women of positive stoma-
tin expression compared with those of negative stomatin
expression (Table 1). There was not statistical difference
in types of surgery (mastectomy vs. lumpectomy)
(Table 1). Most women received an anthracycline-based
chemotherapy as first-line adjuvant chemotherapy. For
women of HER2-positive cancers, there were 4 received
CMF chemotherapy (classical CMF: cyclophosphamide,
methotrexate, and fluorouracil) and one woman received
taxane only because of heart disease. There were 5
women of HER2-positive cancer did not receive any ad-
juvant chemotherapy at all, including 2 women of early
stage and 3 women who refused chemotherapy. There
was not statistical difference in types of chemotherapy
(Table 1). The proportions of patient who had ever re-
ceived trastuzumab therapy were 42 % (15/36) in
stomatin-positive group and 47 % (15/32) in stomatin-
negative group, where there was no statistical difference
in the proportions in receiving trastuzumab (Table 1).
In the 68 women of stage I-IV HER2-positive infiltrat-
ing ductal carcinomas, mean follow-up time was
5.0 years. Kaplan-Meier plot (Fig. 2) showed that the 5-
year breast cancer-specific survival rates were 93 %
(95 % confidence interval = 76 to 98 %) for women of
positive stomatin expression and 65 % for women of
negative stomatin expression (95 % confidence interval
= 38 to 83 %, p = 0.005). Namely, negative stomatin
expression was significantly associated with a lower 5-
year-survival rate. In comparison, there was no survival
difference in patients with HER2-negative breast cancers.
In women of HER2-negative cancers, the 5-year breast
cancer-specific survival rates were 84 % (95 % confi-
dence interval = 67 to 92 %) for women of positive sto-
matin expression and 94 % for women of negative
stomatin expression (95 % confidence interval = 67 to
99 %, p = 0.193).
In the follow-up of 65 women of stage I-III HER2-
positive cancer, there were lung metastases in 5, bone
metastases in 4, liver metastases in 3, lung & bone me-
tastases in 1, lung & liver metastases in 2, distant lymph
nodes metastases in 1, and local recurrence without a
distant metastasis in two women. When the woman of
local recurrence without a distant event was not
Fig. 1 Immunohistochemical staining of breast cancer tissues. I–IV
Expression of stomatin in breast cancer tissue showing the intensity
score. I) Intensity score 0, no brown particles in the tumor cytoplasm
or cell plasma membrane. II) Intensity score 1, faint brown staining
of cell membrane. III) Intensity score 2, weak but definite brown
staining of cell membrane. IV) Intensity score 3, deep brown staining
of cell membrane with staining of cytoplasm
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regarded as failure of disease-free status, 5-year distant
disease-free survival were 81 % (95 % confidence inter-
val = 60 to 92 %) for women of positive stomatin expres-
sion and 57 % for women of negative stomatin
expression (95 % confidence interval = 33 to 75 %, p =
0.016, Fig. 3). In comparison, there was no difference in
patients with HER2-negative breast cancers. The 5-
year distant distant disease-free survival rates were
Table 1 Patient age, tumor characteristics, hormone receptor status, and systemic treatment in relation to stomatin expression in













Mean age (year) 53 58 0.109* 54 52 0.659*
Grade
I 6 4 0.432† 3 1 0.882†
II 27 22 30 15
III 3 6 5 4
Stage
I 9 5 0.420† 13 5 0.857†
II 13 17 12 8
III 13 8 12 7
IV 1 2 1 0
Estrogen receptor
Positive 21 17 0.807† 27 16 0.541†
Negative 15 15 11 4
Progesterone receptor
Positive 20 14 0.466† 25 16 0.366†
Negative 16 18 13 4
Hormonal therapy
No 17 13 0.631† 10 4 0.751†
Yes 19 19 28 16
Surgery
Mastectomy 22 18 0.711† 32 15 0.540†
Lumpectomy 14 13 5 5
No surgery 0 1 1 0
Chemotherapy
None 3 2 0.702† 10 9 0.333†
Adjuvant/Neoadjuvant
Anthracycline 20 20 23 8
Anthracycline + Taxane 8 7 4 3
CMF§ 3 1 0 0
Taxane 1 0 0 0
Palliative
Anthracycline 1 0 1 0
Anthracycline + Taxane 0 2 0 0
Trastuzumab therapy
No 21 17 0.175† N/A N/A N/A
Adjuvant 12 7
Palliative 3 8
*Student’s t test; †Fisher’s exact test; §CMF: classical CMF, cyclophosphamide, methotrexate, and fluorouracil
Chen et al. BMC Cancer  (2016) 16:697 Page 4 of 8
64 % (95 % confidence interval = 46 to 77 %) for
women of positive stomatin expression and 74 % for
women of negative stomatin expression (95 % confi-
dence interval = 46 to 88 %, p = 0.479) for HER2-
negative patients.
For women of HER2-positive cancers, when either
local recurrences or distant metastases were regarded
as failure, the 5-year disease-free survival were 79 %
(95 % confidence interval = 58 to 90 %) for women of
positive stomatin expression and 59 % for women of
negative stomatin expression (95 % confidence inter-
val = 36 to 77 %, p = 0.037).
Although hormonal receptors expression, cancer stage,
and adjuvant trastuzumab therapy were all known prog-
nostic factors for HER2-positive breast cancer, multivari-
ate analyses revealed stomatin was an independent
factor for cancer metastases (p = 0.017, Table 2) for stage
I-III HER2-positive breast cancers. Negative stomatin
Fig. 2 Kaplan-Meier method showing 5-year breast cancer-specific survival curves of HER2-positive infiltrating ductal carcinoma of breast comparing
patients of positive and negative stomatin staining. Significant reduction of proportion surviving was noted in patients of stomatin (−) (n = 32),
compared with patients of stomatin (+) (n = 36). p = 0.005
Fig. 3 Kaplan-Meier method showing 5-year disease-free (distant metastases-free) survival curves of HER2-positive infiltrating ductal carcinoma of
breast comparing patients of positive and negative stomatin staining. Significant reduction of proportion surviving was noted in patients of
stomatin (−) (n = 30), compared with patients of stomatin (+) (n = 35). p = 0.016
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expression predicts distant metastases in a hazard ratio
of 4.0 (95 % confidence interval from 1.3 to 12.5,
Table 2).
Discussion
The present study provides evidence showing a correl-
ation between stomatin protein expression and HER2-
positive breast cancer prognosis. Compatible with a pre-
vious immunohistochemistry study, which showed that
31 % of the breast cancers were negative and 39 % weak
for stomatin staining, the overall immunohistochemistry
staining in our study showed negative staining in 47 %
(32/68) of samples and positive staining in 53 % (36/68)
of samples. Because there was no previous study to de-
fine the positivity according the expression level of sto-
matin, we defined the cutoff point of positive expression
to be a staining index of 4 or more according to a pre-
liminary tome-dependent ROC analysis. It was found
that negative stomatin expression was associated with a
decreased breast cancer-specific survival and disease-
free survival using survival analyses. When distant me-
tastases were defined as cancer recurrence for patients
of stage I-III, stomatin was also an independent prog-
nostic factor using multivariate analysis in this study.
Although stomatin-like protein 2, which is a member of
the stomatin protein family, has been widely reported to be
related to various kinds of cancers, there is only one report
up to the present indicating an association between stoma-
tin expression and carcinogenesis [19]. Arkhipova’s and
colleagues recently reported that down-regulation of sto-
matin mRNA was correlated with positive lymph node
status in 48 patients [19]. In our study, we initially pro-
posed that lipid-raft localized stomatin might be able to
modulate the activity of the HER2-positive breast cancer.
The results that absence of stomatin expression might pre-
dict distant metastases in HER2-positive breast cancer are
comparable to that of Arkhipova’s study for lung cancer
[19].
One reason why previous researchers may have over-
looked the relationship between stomatin and carcino-
genesis may be because only a subgroup of breast
cancers, namely the HER2-positive cancers, is affected
by stomatin expression. In our study, when the 58 pa-
tients with HER2-negative breast cancer were analyzed,
there was no survival difference between the stomatin-
positive group and the stomatin-negative group. Al-
though why stomatin down-regulation is associated with
metastases in HER2-positive cancers remains uncertain,
our results may suggest an interaction between HER2
receptor and stomatin in the lipid raft microdomains.
In Taiwan, 90 % of the invasive breast cancers are infil-
trating ductal carcinoma and less than 4 % are infiltrat-
ing lobular carcinoma, with smaller percentages in other
histology [31]. For reducing bias among different histol-
ogies, we chose women of the commonest histological
type, infiltrating ductal carcinoma, as our study subjects.
In our preliminary study for the histologies other than
infiltrating ductal carcinoma, we can not make any con-
clusion in the influence of stomatin expression to cancer
outcomes because the sample size is too small. Further
large studies are needed to confirm the relationship be-
tween stomatin expression and disease outcomes in
other histological types.
Gene expression patterns have distinguished several
subtypes of breast carcinomas [32]. In a study reported
by Prat el al., all molecular subtypes were identified in
the 468 clinical HER2-positive tumors, including HER2-
enriched (47 %), luminal B (28.2 %), basal-like (14.1 %),
and luminal A (10.7 %) [33]. The molecular subtypes sig-
nificantly affected survival outcomes [33, 34]. In our
study, although stomatin was an independent factor in
multivariate analysis, the molecular patterns of the
tumors were unknown. Future studies exploring gene
expression profiles are warranted.
By definition, disease-free survival usually includes
local or regional recurrence in addition to distant metas-
tases. However, the impact of local recurrences on sur-
vival remains uncertain. Local recurrence itself may be
caused by failed local treatment but not by cancer pro-
gression. In this study, we defined disease-free survival
as time to distant recurrence, excluding local or regional
recurrence. Our study provided the valuable results that
negative stomatin expression predicts distant metastases
in a hazard ratio of 4.0 (95 % confidence interval from
1.3 to 12.5) in multivariate analyses.
Table 2 Multivariate Cox model for distant metastases-free sur-
vival in women of HER2-positive infiltrating ductal carcinoma,
stage I-III (n = 65)
Distant metastases
Parameter Risk ratio (95 % CIa) p
Hormonal receptors‡ 0.405
ER (+) or PR (+) 1.0 (referent)
ER (−) and PR (−) 1.5 (0.6 to 4.3)
Stage 0.016
I–II 1.0 (referent)
III 3.5 (1.3 to 9.9)
Adjuvant trastuzumab 0.147
Yes 1.0 (referent)
No 3.1 (0.7 to 14.8)
Stomatin expression 0.017
Positive 1.0 (referent)
Negative 4.0 (1.3 to 12.5)
‡ER estrogen receptor, PR progesterone receptor
aCI confidence interval
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In randomized controlled trials, patients receiving ad-
juvant trastuzumab showed a significant reduction in
mortality and recurrence as compared to those of no ad-
juvant treatment [35]. The limitation of this study was
that the adjuvant trastuzumab was not used for most
women because of national insurance policy. Only
women had positive lymph nodes were afforded adjuvant
trastuzumab and this policy was effective after 2010. Be-
cause the patients who had ever received adjuvant tras-
tuzumab were a minor group (28 %, 19 of 68, Table 1)
and had a short follow-up time, the influence of trastu-
zumab treatment on stomatin expression could not be
well explored. A clinical trial recruiting more patients is
needed in the future. However, in the multivariate ana-
lyses, stomatin expression was an independent prognos-
tic indicator from trastuzumab treatment, with a higher
hazard ratio than that of adjuvant trastuzumab (hazard
ratio 4.0 vs. 3.1). This result may suggest a different
pathway of cancer progression in stomatin compared to
that of HER2 receptor.
Conclusions
Our findings suggest stomatin as one potential prognos-
tic factor that predicts the progression in HER2-positive
breast cancer. Further studies investigating the mechan-
ism whereby stomatin affects HER2-positive breast can-
cer and how stomatin interacts with HER2 are needed.
Acknowledgements
The authors thank Dr. Pei-Shi Hung in her help with bench works.
Funding
The study was supported by National Science Council Project NSC 99-2314-
B-010-045, MOST 104-2320-B-010-043-MY3, MOST 105-2319-B010-001, Taiwan,
Republic of China.
Availability of data and materials
The datasets during and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
C-Y C, S-S L and C-H L analyzed and interpreted the patient data and were
major contributors in writing the manuscript. C-Y C, C-Y Y, Y-C C, C-W S
performed the histological examination. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Institutional Review Board of National Yang-Ming University Hospital
approved this study. (IRB No.: 2011A011).
Author details
1Institute of Microbiology and Immunology, National Yang-Ming University,
155, Sec.2, Li-Nong St, Taipei 11221, Taiwan, Republic of China. 2Department
of Surgery, National Yang-Ming University Hospital, Yilan County, Taiwan,
Republic of China. 3Department of Education and Research, Taipei City
Hospital, Taipei, Taiwan, Republic of China. 4Department of Pathology,
National Yang-Ming University Hospital, Yilan County, Taiwan, Republic of
China. 5Department of Pathology, Lotung Poh-Ai Hospital, Yilan County,
Taiwan, Republic of China.
Received: 4 February 2015 Accepted: 3 August 2016
References
1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al.
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 1989;244(4905):707–12.
2. Nagy P, Vereb G, Sebestyen Z, Horvath G, Lockett SJ, Damjanovich S, et al.
Lipid rafts and the local density of ErbB proteins influence the biological
role of homo- and heteroassociations of ErbB2. J Cell Sci. 2002;115(Pt 22):
4251–62.
3. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice.
N Engl J Med. 2007;357(1):39–51.
4. Lapatsina L, Brand J, Poole K, Daumke O, Lewin GR. Stomatin-domain
proteins. Eur J Cell Biol. 2012;91(4):240–5.
5. Stewart GW, Argent AC, Dash BC. Stomatin: a putative cation transport
regulator in the red cell membrane. Biochim Biophys Acta.
1993;1225(1):15–25.
6. Stewart GW, Hepworth-Jones BE, Keen JN, Dash BC, Argent AC, Casimir CM.
Isolation of cDNA coding for an ubiquitous membrane protein deficient in
high Na+, low K+ stomatocytic erythrocytes. Blood. 1992;79(6):1593–601.
7. Snyers L, Umlauf E, Prohaska R. Association of stomatin with lipid-protein
complexes in the plasma membrane and the endocytic compartment. Eur J
Cell Biol. 1999;78(11):802–12.
8. Salzer U, Prohaska R. Stomatin, flotillin-1, and flotillin-2 are major integral
proteins of erythrocyte lipid rafts. Blood. 2001;97(4):1141–3.
9. Mairhofer M, Steiner M, Mosgoeller W, Prohaska R, Salzer U. Stomatin is a
major lipid-raft component of platelet alpha granules. Blood. 2002;100(3):
897–904.
10. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;
387(6633):569–72.
11. Mrowczynska L, Salzer U, Perutkova S, Iglic A, Hagerstrand H. Echinophilic
proteins stomatin, sorcin, and synexin locate outside gangliosideM1 (GM1)
patches in the erythrocyte membrane. Biochem Biophys Res Commun.
2010;401(3):396–400.
12. Price MP, Thompson RJ, Eshcol JO, Wemmie JA, Benson CJ. Stomatin
modulates gating of acid-sensing ion channels. J Biol Chem. 2004;279(51):
53886–91.
13. Montel-Hagen A, Kinet S, Manel N, Mongellaz C, Prohaska R, Battini JL, et al.
Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable
to synthesize vitamin C. Cell. 2008;132(6):1039–48.
14. Wang Y, Cao D, Chen J, Liu A, Yu Q, Song X, et al. Distribution of stomatin
expressing in the central nervous system and its up-regulation in cerebral
cortex of rat by hypoxia. J Neurochem. 2011;116(3):374–84.
15. Chen JC, Cai HY, Wang Y, Ma YY, Song LN, Yin LJ, et al. Up-regulation of
stomatin expression by hypoxia and glucocorticoid stabilizes membrane-
associated actin in alveolar epithelial cells. J Cell Mol Med.
2013;17(7):863–72.
16. Lande WM, Thiemann PV, Mentzer Jr WC. Missing band 7 membrane
protein in two patients with high Na, low K erythrocytes. J Clin Invest. 1982;
70(6):1273–80.
17. Liang X, Zhao J, Hajivandi M, Wu R, Tao J, Amshey JW, et al. Quantification
of membrane and membrane-bound proteins in normal and malignant
breast cancer cells isolated from the same patient with primary breast
carcinoma. J Proteome Res. 2006;5(10):2632–41.
18. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al.
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;
28(12):1248–50.
19. Arkhipova KA, Sheyderman AN, Laktionov KK, Mochalnikova VV,
Zborovskaya IB. Simultaneous expression of flotillin-1, flotillin-2, stomatin
and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas.
BMC Cancer. 2014;14:100.
20. Cao W, Zhang B, Liu Y, Li H, Zhang S, Fu L, et al. High-level SLP-2 expression
and HER-2/neu protein expression are associated with decreased breast
cancer patient survival. Am J Clin Pathol. 2007;128(3):430–6.
21. Chang D, Ma K, Gong M, Cui Y, Liu ZH, Zhou XG, et al. SLP-2 overexpression
is associated with tumour distant metastasis and poor prognosis in
pulmonary squamous cell carcinoma. Biomarkers. 2010;15(2):104–10.
Chen et al. BMC Cancer  (2016) 16:697 Page 7 of 8
22. Song L, Liu L, Wu Z, Lin C, Dai T, Yu C, et al. Knockdown of stomatin-like
protein 2 (STOML2) reduces the invasive ability of glioma cells through
inhibition of the NF-kappaB/MMP-9 pathway. J Pathol. 2012;226(3):534–43.
23. Cui Z, Zhang L, Hua Z, Cao W, Feng W, Liu Z. Stomatin-like protein 2 is
overexpressed and related to cell growth in human endometrial
adenocarcinoma. Oncol Rep. 2007;17(4):829–33.
24. Cao WF, Zhang LY, Liu MB, Tang PZ, Liu ZH, Sun BC. Prognostic significance
of stomatin-like protein 2 overexpression in laryngeal squamous cell
carcinoma: clinical, histologic, and immunohistochemistry analyses with
tissue microarray. Hum Pathol. 2007;38(5):747–52.
25. Zhang L, Ding F, Cao W, Liu Z, Liu W, Yu Z, et al. Stomatin-like protein 2 is
overexpressed in cancer and involved in regulating cell growth and cell
adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res.
2006;12(5):1639–46.
26. Yeoh LC, Loh CK, Gooi BH, Singh M, Gam LH. Hydrophobic protein in
colorectal cancer in relation to tumor stages and grades. World j
gastroenterol: WJG. 2010;16(22):2754–63.
27. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R.
Laboratory assessment of the status of Her-2/neu protein and oncogene in
breast cancer specimens: comparison of immunohistochemistry assay with
fluorescence in situ hybridisation assays. J Clin Pathol. 2000;53(5):374–81.
28. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored
survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.
29. R Core Team R: A Language and Environment for Statistical Computing
[https://www.R-project.org]. Accessed 24 Aug 2016.
30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations.
J Am Stat Assoc. 1958;53:457–81.
31. Taiwan Cancer Registry [http://tcr.cph.ntu.edu.tw/main.php?Page=N1].
Accessed 24 Aug 2016.
32. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene
expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.
33. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou
CM, Baselga J. Molecular features and survival outcomes of the intrinsic
subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014;106(8):
1–8.
34. Falck AK, Ferno M, Bendahl PO, Ryden L. St Gallen molecular subtypes in
primary breast cancer and matched lymph node metastases–aspects on
distribution and prognosis for patients with luminal A tumours: results from
a prospective randomised trial. BMC Cancer. 2013;13:558.
35. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant
trastuzumab in the treatment of her-2-positive early breast cancer: a meta-
analysis of published randomized trials. BMC Cancer. 2007;7:153.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. BMC Cancer  (2016) 16:697 Page 8 of 8
